Men Tongyi, Zhang Xiaoming, Yang Jiwei, Shen Bin, Li Xianduo, Chen Dongdong, Wang Jianning
Department of Urology, Qianfoshan Hospital Affiliated to Shandong University, 283 Jingwu Rd, Huaiyin District, Jinan, 250012, China.
Tumour Biol. 2014 Jan;35(1):269-75. doi: 10.1007/s13277-013-1035-1. Epub 2013 Aug 23.
Glutathione peroxidase (GPX) is an endogenous antioxidant enzyme counteracting oxidative stress. Accumulating evidence has demonstrated that the GPX1 rs1050450 C > T polymorphism may modulate cancer risk, but the association of GPX1 rs1050450 polymorphism with bladder cancer (BC) and prostate cancer (PCa) is still inconclusive. This meta-analysis was designed to determine the exact association of GPX1 rs1050450 C > T polymorphism with the risk of bladder cancer and prostate cancer. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated to estimate the association strength. Databases of PubMed, EMBASE, and China National Knowledge Infrastructure were searched to retrieve eligible studies. In total, ten eligible studies with 6,194 participants were included. By pooling all eligible studies, we found that carriers of the variant T allele were associated with a significantly increased risk of urinary tract cancer (T vs. C: OR = 1.459 and 95% CI, 1.086-1.962; CT/TT vs. CC: OR = 1.411 and 95 % CI, 1.053-1.891). In stratified analysis, we observed that the rs1050450 C > T polymorphism was significantly associated with an increased risk of BC (T vs. C: OR = 2.111 and 95% CI, 1.020-4.368; CT/TT vs. CC: OR = 1.876 and 95% CI, 1.011-3.480), while the association was not significant for PCa. Egger's test and Begg's test revealed no publication bias. The present meta-analysis provides evidence that the GPX1 rs1050450 C > T polymorphism leads to an increased risk of BC but not the risk of PCa.
谷胱甘肽过氧化物酶（GPX）是一种对抗氧化应激的内源性抗氧化酶。越来越多的证据表明，GPX1基因rs1050450位点C>T多态性可能会调节癌症风险，但GPX1基因rs1050450多态性与膀胱癌（BC）和前列腺癌（PCa）的关联仍无定论。本荟萃分析旨在确定GPX1基因rs1050450位点C>T多态性与膀胱癌和前列腺癌风险的确切关联。计算比值比（OR）和95%置信区间（CI）以估计关联强度。检索了PubMed、EMBASE和中国知网数据库以获取符合条件的研究。总共纳入了10项符合条件的研究，涉及6194名参与者。通过汇总所有符合条件的研究，我们发现携带变异T等位基因的个体患尿路癌的风险显著增加（T与C相比：OR = 1.459，95%CI为1.086 - 1.962；CT/TT与CC相比：OR = 1.411，95%CI为1.053 - 1.891）。在分层分析中，我们观察到rs1050450位点C>T多态性与BC风险增加显著相关（T与C相比：OR = 2.111，95%CI为1.020 - 4.368；CT/TT与CC相比：OR = 1.876，95%CI为1.011 - 3.480），而与PCa的关联不显著。Egger检验和Begg检验未显示发表偏倚。本荟萃分析提供了证据表明，GPX1基因rs1050450位点C>T多态性会导致BC风险增加，但不会导致PCa风险增加。
